Related Experiment Video
Updated: Sep 15, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial
Lena Roth1, Nico Steckhan1, Peter E H Schwarz1
1Department for Prevention and Care of Diabetes, Department of Medicine III, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Aims:
Digital applications have the potential to enhance diabetes management, particularly in patients treated with insulin. This study aims to evaluate the impact of a digital application on self-management (ESYSTA, Germany), expressed in a change in HbA1c levels, in people with diabetes treated with insulin.
Materials And Methods:
A randomized controlled, multicentric trial was conducted in 204 people with diabetes (60% type 2 diabetes) treated with insulin to assess the efficacy of ESYSTA. Participants were randomly assigned to either the intervention group (IG) using ESYSTA in addition to the German standard of Care (SoC) according to the German disease management programs (DMP) for 6 months or a control group (CG) receiving SoC only. The primary endpoint was the change in HbA1c levels. Secondary endpoints included well-being and diabetes-related distress.
Results:
A clinically relevant reduction in HbA1c levels of on average -0.48% points (-0.66; -0.29) was observed in the IG after 6 months. Compared to the CG, this reduction was more pronounced, especially in the per-protocol sample [mean difference, -0.28% points; 95% CI (-0.54; -0.02)]. Improvements in the IG in further secondary endpoints, such as well-being or diabetes-related distress, indicate enhanced overall glycemic control and patient satisfaction in the IG.
Conclusions:
The use of ESYSTA improved HbA1c levels and other secondary outcomes in people with diabetes who are treated with insulin in comparison with German SoC in the context of DMP. These findings support the integration of digital tools in routine diabetes care to optimize patient outcomes.
Clinical Trial Registration:
https://drks.de/search/de/trial/DRKS00025996, identifier DRKS00025996.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
04:24A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...